Zdrowie i gospodarka · 26/09/2014

FDA to Host Public Meeting and Scientific Workshop on Female Sexual Dysfunction

The FDA is hosting a public meeting and scientific workshop to gather patient perspectives and expert input on Female Sexual Interest/Arousal Disorder (FSIAD), a diagnosis combining hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD), as part of its Patient-Focused Drug Development performance commitments under the Prescription Drug User Fee Act (PDUFA V).